Dr Reddy’s forays into Indian biosimilar immuno-oncology market | Hyderabad News
Hyderabad: Pharma major Dr Reddy’s Laboratories on Tuesday announced its foray into the Indian biosimilar immuno-oncology market with the rollout of its biosimilar version of Bristol Myers Squibb’s Opdivo (nivolumab).The biosimilar — Nivorz, developed and manufactured entirely in-house at its biologics facility in Bachupally, Hyderabad — has been approved by Drugs Controller General of India…
